Ion Beam Applications SA (IBAB)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 15.84 |
|---|---|
| 52-week range | 9.90 – 17.76 |
| Return, 1 month / 3 months | +2.3% / −5.0% |
| Return, 1 year / 3 years | +43.4% / +85.0% |
| Trend | Uptrend |
| RSI (14) | 50 |
| Volatility (1 year) | 31.6% |
| Worst drawdown (1 year) | -22.6% |
| Average daily value traded | 0.28M EUR |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ion Beam Applications SA, often called IBA, is a Belgian company that designs and builds equipment based on particle accelerators. Its main business is proton therapy systems, which hospitals use to treat cancer patients with precisely aimed beams of protons. The company also supplies cyclotrons and related equipment for producing medical radioisotopes and for industrial and research uses. It is based in Louvain-la-Neuve, Belgium, and serves hospitals, research centres and industrial customers around the world.
Ion Beam Applications SA trades under the code IBAB on the Euronext Brussels in Belgium, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ion Beam Applications SA (IBAB) trades on the Euronext Brussels in Belgium. It last closed at EUR 15.84 on 22 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 42 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 43.4% and over the last three months it fell 5.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 3.6% | ||
| From 52-week high | -10.6% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -5.0% | ||
| 6-month return | 12.1% | ||
| 12-month return, skipping the last month | 40.2% | ||
| Stability (higher is calmer) | 47 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 31.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.6% | ||
| Liquidity | 56 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.28M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.2% |
|---|---|
| 1 month | +2.3% |
| 3 months | −5.0% |
| 6 months | +12.1% |
| 1 year | +43.4% |
| 3 years | +85.0% |
| 5 years | −2.4% |
Signals
| 50-day / 200-day average | 15.70 / 15.28 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.42 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Jun 2026 | EUR 0.1750 |
| 18 Jun 2025 | EUR 0.1680 |
| 19 Jun 2024 | EUR 0.1190 |
| 29 Jun 2023 | EUR 0.1470 |
| 29 Jun 2022 | EUR 0.1330 |
| 21 Jun 2021 | EUR 0.1400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.